Caffeine, CYPA12 and Resistance Training
Influence of CYP1A2 on the Prolonged Effect of Caffeine Intake on Resistance Training
Alberto Pérez-López
48 participants
Apr 1, 2024
INTERVENTIONAL
Conditions
Summary
Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to be elucidated how CYP1A2 polymorphism influences the prolonged effects of caffeine on this type of exercise. Objectives: The present study aims to analyze the prolonged effects of caffeine intake on neuromuscular adaptations to resistance training according to CYP1A2 polymorphism in men and women.
Eligibility
Inclusion Criteria5
- Age between ≥ 18 and ≤ 35 years.
- Body mass index (BMI) lowe than 25 kg/m².
- Physically active subjects (≥ 150 min/week of moderate exercise).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
- Participants capable of performing the tests.
Exclusion Criteria7
- History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
- Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
- Body mass index (BMI) ≥ 25 kg/m².
- Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
- Performing strenuous exercise within 48 hours prior to the tests.
- Failing to replicate the same food intake on the two experimental days.
- Consuming caffeine after 6 PM on the day prior to training or testing.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Acute caffeine intake (3 mg/kg) prior each resistance training session of a 8 weeks training program.
Acute placebo intake (3 mg/kg of maltodextrin) prior each resistance training session of a 8 weeks training program.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06610123